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Context: Appetite-related hormones may play an important role in weight regain after obesity
therapy.
Objective:Ourobjectivewas to investigate thepotential involvementofghrelin, leptin, and insulin
plasma levels in weight regain after a therapeutic hypocaloric diet.
Design: A group of obese/overweight volunteers (49 women and 55 men; 35  7 yr; 30.7  2.4
kg/m2) followed an 8-wk hypocaloric diet (30% energy expenditure) and were evaluated again
32 wk after treatment. Body weight as well as plasma fasting ghrelin, leptin, and insulin concen-
trations were measured at three points (wk 0, 8, and 32).
Results: After the 8-wk hypocaloric diet, the average weight loss was 5.0  2.2% (P  0.001).
Plasma leptin and insulin concentrations decreased significantly, whereas ghrelin levels did not
markedly change. In the group regaining more than 10% of the weight loss, leptin levels were
higher (P  0.01), whereas ghrelin levels were lower (P  0.05). No differences were observed in
insulin levels. Weight regain at wk 32 was negatively correlated with ghrelin and positively asso-
ciatedwith leptin levels at baseline (wk 0) and endpoint (wk 8). These outcomes showed a gender-
specific influence, being statistically significant among men for ghrelin and between women for
leptin. Moreover, a decrease in ghrelin after an 8-wk hypocaloric diet was related to an increased
risk for weight regain (odds ratio 3.109; P 0.008) whereas a greater reduction in leptin (odds
ratio  0.141; P  0.001) was related to weight-loss maintenance.
Conclusions: Subjectswith higher plasma leptin and lower ghrelin levels at baseline could bemore
prone to regain lost weight, and hormones levels could be proposed as biomarkers for predicting
obesity-treatment outcomes. (J Clin Endocrinol Metab 95: 5037–5044, 2010)
The prevalence of obesity continues to riseworldwide (1).This metabolic disorder is associated with several co-
morbidities such as diabetes and cardiovascular and neuro-
degenerative diseases as well as some types of cancer (2).
Diverse therapeutic strategies have been tried to de-
crease body adiposity. Nutritional interventions, such as
caloric restriction diets, can be an efficient therapeutic ap-
proach to promote weight loss in obese subjects (3). Al-
though most therapeutic trials involving drugs (4) or di-
etary treatments can showmeanweight losses higher than
5% of body weight (5, 6), the long-term success of main-
taining the lost weight is usually poor (7). Therefore, the
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identification of factors associated with weight regain can
enhance our understanding of energy homeostasis regu-
lation and would have positive implications for the per-
sonalization of therapeutic approaches.
Several biological and psychological factors may con-
tribute to the weight regain after a treatment-induced
weight loss (8). There is also evidence that some weight
reduction therapies fail long term due to compensatory
adaptations in metabolism, which promote rapid and ef-
ficient weight regain (9). Among the mechanisms impli-
cated, orexigenic and anorexigenic hormones appear to
have a clinically relevant role (10).
Ghrelin is a circulating orexigenic hormone (11),which is
implicated in both the short-term control of food intake at
single meals and in long-term body-weight regulation (12).
Furthermore, insulin and leptin are two key endocrine adi-
posity factorsproviding signaling for the centralnervous sys-
tem to regulate food intake (13). Indeed, there is a complex
interaction between insulin, leptin, and ghrelin; leptin regu-
lates ghrelin levels and affects changes in body weight,
whereas insulin and ghrelin are involved in the physiological
response to food intake and are reciprocally regulated (14).
The aim of the present study was to evaluate whether
plasma levels of ghrelin, leptin, and insulin can influence
weight regain after an energy-restricted therapyandwhether
they may be used to identify those subjects more prone to
regain the weight loss induced by a hypocaloric diet.
Subjects and Methods
Study subjects
The study protocol initially included 162 obese/overweight
subjects [79 women and 83 men; 35  6 yr; with a mean body
mass index (BMI) of 31.1  2.9 kg/m2] recruited through local
advertisements. All participants provided a medical history,
physical examination, and routine laboratory tests. Exclusion
criteria were history of diabetes mellitus, high blood pressure, or
dyslipidemia or changes in body weight greater than3 kg during
the 3 months before the study. Other exclusion criteria included
pregnancyandprevious surgicallyordrug-treatedobesityaswell as
alcohol or drug abuse. Furthermore, consumption of vitamin or
mineral supplements as well as regular prescription of medical
drugsduring this timewasnotallowedandwere further reasons for
exclusion. Written informed consent to participate in the trial was
obtained before the start of the study. The protocol used for this
studywas approved by the Clínica Universitaria deNavarra Ethics
Committee (Ref. 54/2006), in agreement with the Helsinki Decla-
ration, and followed national and European Union guidelines.
Study design
The trial was based on a nutritional intervention controlled
by traineddieticians from theDepartment ofNutrition andFood
Sciences, Physiology, and Toxicology of the University of Na-
varra. Weight loss was induced by means of a hypocaloric diet
devised toproduce a30%energy restriction (500–600kcal/d) of
the subject’s total energy expenditure. This estimation was cal-
culated by applying Harris-Benedict equations and a correction
factor based on the overweight status of the subjects, which was
adjusted for the level of physical activity (15). The pattern of
physical activity remained unchanged in all stages and was as-
sessed and controlled by a trained specialist, based on a validated
physical activity questionnaire for overweight individuals (16).
The nutritional intervention program consisted of 8 wk of a
balanced hypocaloric diet containing 55% of the energy supply
as carbohydrates, 15% as proteins, and 30% as fat, which was
implemented by a food exchange system (17). Dietary compli-
ance was assessed through 3-d weighed food records (5, 18).
Calculations of the energy and nutrient intake were performed
using appropriate software (Sanocare Human System L.S., Ma-
drid, Spain) based on recognized Spanish food composition ta-
bles. Food questionnaires were completed during the week be-
fore the beginning of the intervention and 1 wk before the
completion of the hypocaloric diet. These reports provided in-
formation on the baseline intake and the adherence to the pre-
scribed diets (17). Before and after the nutritional treatment,
selected anthropometric measurements were taken.
Upon completion of the dietary intervention (wk 8), volun-
teerswere givengeneral dietary guidelines tomaintain theweight
loss, but without calorie restrictions or specific follow-up in-
structions. Subjects were instructed on healthy habits, such as
dietary intake and physical activity, following the Spanish Soci-
ety for the Study of Obesity (SEEDO) guidelines and the Nutri-
tion and Physical Activity for Obesity Prevention Strategy
(NAOS) guidelines from theHealthMinistryof the SpanishGov-
ernment. Six months later (wk 32), 104 subjects returned to the
clinical research unit for further assessment. Their dietary pat-
ternswere estimated fromfoodquestionnaires, and their changes
in body weight were measured.
Venous blood sampleswere drawn after a 12-h overnight fast
and were obtained at the beginning of the restriction diet (base-
line, wk 0), at the end of the diet intervention (endpoint, wk 8),
and 6months after ending the treatment (follow-up,wk32). The
EDTA-plasma and serum of specimens were separated from
whole blood and immediately frozen at 80 C until assay.
Anthropometric and body composition measurements were
performed according to standardized procedures described else-
where (15).
Hormone assays
Overnight fasting plasma levels of ghrelin were measured by
RIA using a commercially available kit (Linco Research Inc., St.
Charles, MO). This assay is able to detect both acylated and
deacylated ghrelin. Serum concentrations of insulin and leptin
were assessed using a RIA-based method (Diagnostic Products
Corp., Los Angeles, CA).
Statistical analysis
The sample size of the current interventional trial was esti-
mated taking theweight loss after treatment (main variable) into
account and calculated according to the equation reported by
Mera et al. (19). Thus, to detect differences, the sample size was
established at a minimum of 85 obese/overweight subjects who
finished the nutritional intervention. The original sample size
recruited was 162 obese/overweight volunteers who completed
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the hypocaloric diet. Six months later, 104 subjects returned to
the study site for further assessment. To reinforce the results,
statistical analysis was performed using only the 104 subjects
that completed the three points (wk 0, 8, and 32) of this study,
and the median criterion was applied to avoid dropout impact.
Diet-induced changes in body weight and hormone values
were calculated (in percent) as the difference between endpoint
(wk 8) and baseline (wk 0) measurements and related to the
baseline. To analyze the high or low changes of hormone levels
during the intervention, the median (above and below the 50th
percentile) cutoff values of the changes in these variables were
considered in the analyzed population as previously applied (15)
andbasedonavalidatedmethod toassign the studiedpopulation
to two groups of disease risk (16). Body weight loss was also
dichotomized according to the 5% of weight loss criterion.
Weight regain (percent) was calculated as the difference between
the follow-up period (wk 32) and endpoint (wk 8) with respect
to the endpoint values. Successful weight-loss maintenance was
considered by using the criterion of the 10% weight regain, ac-
cording to previously published reports (15).
The normal distribution of variables was explored using the
Kolmogorov-Smirnov and the Shapiro Wilk tests. Accordingly,
the parametric Student’s t or nonparametric Wilcoxon paired
test was applied to detect differences before and after the treat-
ment. Moreover, differences between the groups at all points of
the nutritional trial were assessed by the parametric Student’s t
or nonparametric Mann-Whitney U test. A repeated-measures
ANOVA was used to study the effects of time and groupings on
body weight and hormone levels. The Pearson coefficient was
used to evaluate the potential association between body weight
regain and hormone levels before and after dieting. In addition,
a logistic regression analysis was applied to assess the potential
predictive factors concerning body weight regain. Thus, as in-
dependent variables, median cutoff values were used to classify
the hormone diet-induced changes. Success in weight-loss main-
tenance was used as the dependent variable.
Statistical analysis was performed by SPSS version 13.0 soft-
ware (SPSS Inc., Chicago, IL) forWindows XP (Microsoft, Red-
mond, WA). P  0.05 was considered statistically significant.
Results
Changes in anthropometric parameters as well
as in ghrelin, leptin, and insulin levels after
nutritional intervention
After the 8-wk energy restriction period, patients lost
an average of 5.0 2.2% body weight (4.5 1.9% for
women vs. 5.9  2.2% for men; P  0.001) accompa-
nied by a statistically significant reduction in BMI and
body fatmass, fat-freemass, andwaist circumference (Ta-
ble 1). The hypocaloric diet also induced a significant de-
crease in leptin and insulin levels, whereas ghrelin con-
centrations remained unaltered (Table 1). These changes
were also statistically different when the subjects were
sorted according to the 5% of weight loss criteria. Thus,
decreases in plasma leptin and insulin were greater in sub-
jects who lost at least 5% of their body weight, and no
statistical differences in ghrelin levels were found between
the two groups (Table 2).
After the follow-up period (wk 32), as a group, subjects
maintained the body weight as compared with the end-
point (84.42  13.22 vs. 84.74  11.36 kg; P  0.1).
When patients were categorized according to the 10% of
weight regain classification criterion, a total of 55 subjects
(25 females and 30 males) maintained the weight loss
[weight-maintenance group (WM group), 5.39 
4.09%] and 49 subjects (24 females and 25 males) re-
gained at least 10% of the lost weight [weight-regain
group (WR group), 5.17 5.02%]. As expected, after the
follow-up period, the WR group presented a statistically
(P 0.001) higher body weight (84.74 14.41 kg) than
the WM group (79.68  10.01 kg).
Overall, gender-specific differenceswere found in body
weight and hormone levels. Thus, it was observed that
women presented lower body weight than men in all
points of the study (P  0.001). Moreover, leptin and
ghrelin levels were statistically higher in females than
TABLE 1. Phenotypical characteristics and changes in
anthropometrical and biochemical variables before and
after the caloric restriction (CR) treatment in 49 women
and 55 men (35.6  6.6 yr old)
Before CR
(wk 0)
After CR
(wk 8)
P
value
Body weight (kg) 89.5  12.3 84.7  11.3 0.001
BMI (kg/m2) 30.7  2.4 29.0  2.2 0.001
Fat-free mass (kg) 61.1  12.3 58.9  11.9 0.001
Fat mass (%) 32.9  7.7 31.3  8.1 0.001
Waist circumference
(cm)
96.2  8.2 92.1  7.9 0.001
Leptin (ng/ml) 22.5  14.7 14.9  14.5 0.001
Ghrelin (pg/ml) 952  326 964  343 0.461
Insulin (mU/liter) 9.28  4.68 7.36  3.63 0.001
TABLE 2. Diet-induced changes of leptin, insulin, and ghrelin according to 5% of weight loss grouping criteria
between baseline and wk 8
>5% body
weight-loss group
<5% body
weight-loss group P value
Weight loss (% change) 6.98  1.87 3.65  0.95 0.001
Leptin (% change) 51  17 28  26 0.001
Insulin (% change) 7.0  1.9 3.6  0.9 0.001
Ghrelin (% change) 5.3  22.8 0.5  16.1 0.140
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males (P 0.001) but with no statistical differences in the
insulin concentration between either gender categories.
Based on this gender dimorphism, the differences be-
tween WR and WM groups were evaluated separately in
both gender categories. Thus, body weight and insulin
changes betweenWR andWMwere similar between men
and women. Furthermore, leptin levels were significantly
higher at all three points in WR compared with WM
women (Fig. 1B). In contrast, in men, no differences be-
tween groupswere observed (Fig. 1A). Ghrelin levels were
significantly higher at baseline and wk
8 inWR compared withWMmen (Fig.
1A), whereas women showed no statis-
tical differences (Fig. 1B).
A correlation analysis showed that
lower baseline (wk 0) and lower end-
point (wk 8) plasma levels of ghrelin
(Fig. 2, A and B), especially in men, as
well as higher leptin (Fig. 2, C and D)
concentrations, especially in women,
were significantly associated with higher
weight regain.No associationwas found
between the baseline (r  0.013; P 
0.894) or endpoint (r  0.047; P 
0.639) insulin levels and body weight
regain. Moreover, weight regain was
positively associated with the diet-in-
duced changes of leptin (Fig. 2F) and
tended to correlate inversely with
the changes in ghrelin after dieting
(Fig. 2E).
Association between ghrelin,
leptin, and insulin hypocaloric
diet-induced changes and the
body weight evolution
To further investigate the influence of
theassayedhormonelevelsafter theenergy
restrictiontreatmentonbodyweightmain-
tenance, the subjects were categorized
into two groups according to themedian
of the diet-induced (wk 0–8) changes in
ghrelin (2.1%), leptin (44.9%) and in-
sulin (21.9%) levels. Patients exhibit-
ing changes fromwk0 towk 8 in ghrelin
below the median (P  0.023) and
changes in insulin (P 0.049) and leptin
(P  0.022) above the median showed
greater weight regain (Fig. 3).
To further assess the effect of the
evaluated hormones on weight regain,
a logistic regression analysis was per-
formed to investigate potential predic-
tors of weight regain. Thus, after adjusting for the age,
gender, and amount of weight loss, the changes in ghrelin
and leptin (as dichotomous variables) from wk 0 to wk 8
appeared as potential predictors of weight regain (Table
3). A diet-induced (wk 0–8) decrease in ghrelin was re-
lated to an increased risk for weight regain (odds ratio 
3.109; P  0.008) whereas a diet-induced (wk 0–8) de-
crease in leptin (odds ratio  0.141; P  0.001) was re-
lated to weight-loss maintenance.
FIG. 1. Men’s (A) and women’s (B) body weight and plasma insulin, leptin, and ghrelin levels
during the nutritional treatment (wk 0–8) as well as follow-up period, 6 months later (wk 32),
depending on the weight maintenance group (n  104). The follow-up data for ghrelin levels
are shown, but they were not included in the statistical analysis due to insufficient blood
samples (n  31). Data show mean  SE. WM, Subjects with successful weight maintenance;
WR, subjects with weight regain. Asterisks denote statistical changes (*, P  0.05; **, P 
0.01; ***, P  0.001) between WM groups at each time point of the study evaluated by
Student’s t test according to the normal distribution of the variables. §, Statistically significant
(P  0.05) changes across time; †, changes concerning the group; ‡, statistical significance
for the time-group interaction evaluated by means of a repeated-measures ANOVA. CR,
Calorie restriction.
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Discussion
After a nutritional intervention to induce weight loss, the
prevention of weight regain is the most clinically relevant
issue in the efforts to reduce the epidemic of obesity. The
novel findings from this study are that after a weight re-
duction induced by an 8-wk balanced hypocaloric diet,
subjects who regained at least 10% of the lost weight 6
months later appeared to have higher fasting leptin levels
and lower fasting ghrelin levels at all times during the
study than those thatmaintainedbodyweight. In contrast,
no significant differences were found in
the concentrations of fasting insulin.
These responses had a gender-specific
dependence. In addition, the energy-re-
stricted diet-induced changes in fasting
leptin and ghrelin appear as important
risk predictors for regaining the lost
weight.
Differential outcomes are often
found when classifying patients as re-
sponders and nonresponders to chemo-
therapy (20) or antidiabetic (21) treat-
ments. Concerning obesitymanagement,
important weight loss variability among
individuals is encountered due to factors
such as metabolic adaptations (9) or ge-
netic predisposition (15, 22). Therefore,
the identification of predictive factors
concerning the treatment response is cru-
cial to individualize therapies and to
avoid the prescription of therapies in pa-
tients with potential resistance.
Several studies have shown reduc-
tions in leptin and insulin levels (5), to-
gether with an increase in ghrelin levels
(23, 24) inducedbydifferentweight loss
therapies. In agreement with such pre-
vious reports, the balanced hypocaloric
diet applied to loseweight in the current
workalso induced a significant decrease
in insulin and leptin levels after 8wk.At
the same time, ghrelin levels showed a
small although not statistically signifi-
cant increase after dieting.
Despite the demonstrated beneficial
effect of an energy-restricted diet on
obesity comorbidity risk factors (18,25,
26), changes in appetite-regulating hor-
mones have been hypothesized to occur
with weight loss and may facilitate
rapid and efficient weight regain after
treatment (9). It has been demonstra-
ted that subjectswithout a significantweight loss (5%of
initial weight) under dieting showed a compensatory in-
crease of ghrelin levels that could explain the lack of rel-
evant weight loss (23). In the present study, lower de-
creases in leptin and insulin levels were found in subjects
who lost less than 5% of the initial weight. In accordance
with other authors (27), ghrelin levels were no different
depending on weight loss, although subjects without signif-
icant weight loss showed a lower increase in ghrelin. These
discrepancieswithprevious reports couldbedue to technical
FIG. 2. Association between plasma ghrelin and leptin levels at baseline (A and B,
respectively) and after 8 wk caloric restriction treatment (C and D, respectively), as well as the
diet-induced changes in ghrelin (E) and leptin (F) with body weight regain 6 months after
finishing dietary intervention. Those subjects who presented lower ghrelin and higher leptin
fasting plasma levels after energy restriction treatment regained the lost body weight in the 6
months of follow-up.
J Clin Endocrinol Metab, November 2010, 95(11):5037–5044 jcem.endojournals.org 5041
and experimental approaches (27).However, when the sub-
jects included in this studywere categorized into two groups
according to success in bodyweightmaintenance, those sub-
jects who regained at least 10% of the lost weight showed
higher levels of leptin and lower levels of ghrelin. Interest-
ingly, these hormonal differences were found at all times
including baseline, suggesting the existence of two differ-
ent populations according to the leptin and ghrelin levels
influencing the response outcomes.
Insulin presented a profile in accordance with the body
weight course changes during the trial, showing differ-
ences betweenWMandWRonly atwk32.Thereafter, the
insulin data support the suitability of the classification of
subjects applied in this trial to evaluate the differential
weight regain status. On the other hand, whereas insulin
levels did decrease from baseline to wk 8 in both WR
andWMmen and women, by wk 32, insulin levels were
higher than baseline in both men and women in the WR
group and returned to baseline levels in the WM group.
In contrast, body weight at follow-up was not higher
than at baseline in theWR group, and it remained lower
than baseline in the WM group. Therefore, the findings
in the WR group suggest that metabolically, this group
was less insulin sensitive at the same body weight after
cycling through weight loss/weight regain. The findings
in the WM group suggest that insulin sensitivity im-
proved with energy restriction rather than with weight
loss.
Because ghrelin is a potent orexigenic signal and leptin
is a satiety signal, a coordinated change in these hormone
levelsmay elicit strong compensatory increases in appetite
and weight gain (28). In agreement with this statement, it
may be expected that those subjects who regain more eas-
ily the lost weight showed lower levels of leptin and higher
levels of ghrelin. However, that was not the case, and the
present results are consistent with a disruption in the sen-
sitivity to these hormone signals, probably in the central
nervous system of those subjects with a higher predispo-
sition to regain body weight.
Previous reports and also the present study (data not
shown) found a negative association between circulating
ghrelin levels and BMI (29), postulating an increase in
ghrelin secretion during fasting, malnutrition, cachexia,
and anorexia nervosa and reduced ghrelin secretion in
obesity. Ghrelin administration does not affect appetite in
anorexia nervosa patients, suggesting that they are less
sensitive to ghrelin in terms of food intake (30). These
findings suggest altered ghrelin signaling in obesity and
anorexia nervosa, the mechanisms of which are not pres-
ently understood.
The regulation of ghrelin is complex and is under genetic
andother patient-related influences. Several polymorphisms
or distinct mutations have been identified in the preprogh-
relin locus and in its receptor [growthhormone secretagogue
receptor (GHS-R)] as well as additional GHS-R subtypes or
other receptor families (31)or ligandsother thanghrelin that
may act on the GHS-R (32), which may influence a wide
range of biological roles.
In the same line, obesity in humans is commonly asso-
ciated with increased leptin levels, but despite the anorex-
igenic function of this hormone, appetite is not effectively
suppressed. This phenomenon, called leptin resistance,
could be the result of impairments at a number of levels in
the signalingpathway fromreducedaccess of thehormone
to its receptor through changes in receptor expression or
changes in postreceptor signal transduction (33).
Reinforcing the present results, it was found that base-
line and endpoint levels of ghrelin and leptin could explain
the variability in the body weight regain after the energy
restriction treatment. Thus, higher levels of ghrelin pre-
dicted no body weight regain, especially in men. At the
same time, higher leptin levels were associated with body
weight regain more specifically in women. Moreover, ad-
TABLE 3. Logistic regression analysis to determine the
risk of regaining more than 10% of weight loss after a
diet-induced weight loss
OR 95% CI
P
value
Model 1: ghrelin change 3.109 1.346–7.181 0.008
Model 2: leptin change 0.141 0.044–0.454 0.001
Model 3: insulin change 0.541 0.233–1.256 0.153
The ghrelin, leptin, or insulin diet-induced changes classified as
dichotomous variables according to the median cutoff value (reference
is values below the median) were considered as independent variables.
The model was adjusted by gender, age, and weight loss (percent).
The weight regain (dependent variable) was encoded as 0 for weight
maintenance (10% of weight regain) and 1 for weight regain
(10% of weight regain). Changes in ghrelin, leptin, and insulin were
encoded as 0 for diet-induced increase or values above the median
and 1 for diet-induced decrease or values below the median. CI,
Confidence interval; OR, odds ratio.
FIG. 3. Differences in body weight regain of subjects categorized
according to the median of the diet-induced (wk 0–8) changes in
insulin, leptin, and ghrelin. Data show mean  SE. *, Statistically
significant differences between both groups.
5042 Crujeiras et al. Appetite Hormones and Regain of Weight J Clin Endocrinol Metab, November 2010, 95(11):5037–5044
justed by gender, age, and weight loss, the diet-induced
changes in leptin and ghrelin were found to be protective
factors of regaining the lost weight. These reports are in
contrast to the hypothesis concerning the role of the
weight loss-induced changes in these appetite hormones as
metabolic adaptations to weight reduction that promote
efficientweight regain. This statement usually comes from
trials that do not evaluate body weight maintenance after
treatment (23, 24) or from experiments with genetic and
pharmacological manipulations of key components of the
appetite hormone in animalmodels (34).On the contrary,
the present results were obtained from humans on a mod-
erate and balanced hypocaloric diet where subjects were
given dietary guidelines tomaintain weight loss, but with-
out caloric restrictions or specific follow-up instructions.
In this regard, it has been previously observed in obese
humans that the appetite evaluated by a validated visual
analog scale is inversely associated with ghrelin concen-
trations (35). Another report has found higher ghrelin
concentrations in obese subjects fed a hypocaloric diet
enriched in n-3 polyunsaturated fatty acids which have
positive effects on weight loss (36) and on decreases in the
sensation of hunger (35). Moreover, higher decreases in
leptin levels induced by a fish-based energy-restricted diet
were associatedwith bettermetabolic improvements, sug-
gesting that weight maintenance control could be en-
hanced (5).
On the other hand, the findings of this trial are consis-
tentwith an advancedproinflammatory state in those sub-
jects more prone to regain the diet-induced weight loss
(15) because leptin has been proposed as a proinflamma-
tory adipokine (37), whereas ghrelin appears to have an-
tiinflammatory and antioxidant properties (38). Thus,
leptin and ghrelin levels found in those subjects who are
able to maintain the weight loss after treatment could be
in accordance with a lower susceptibility to develop obe-
sity-related morbidities. Finally, beside the widely dem-
onstrated gender-specific differences in leptin levels (39),
some studies have also reported gender differences in
plasma ghrelin levels in normal subjects (40).However, as
far as we know, this work presents for the first time that
higher plasma ghrelin concentrations were found in obese
women than in men.
A limitation of this study could be the single fasting
hormone levels employed because insulin, leptin, and gh-
relin concentrations can be dramatically influenced by
food intake and can bemodified by severalmetabolic con-
ditions.However, fastinghormone level is a representative
sample of baseline conditions, without influence of pre-
prandial and postprandial factors. In fact, the evaluation
of fasting hormone level is usually a reference point to
compare two or more populations and under different
conditions. On the other hand, leptin concentration at
fasting is representative of the 24-h levels. Moreover, the
assay of the area under curve values is a nuisance to the
patients, and it has a high economic cost. Because of these
reasons, we decided to evaluate the hormone levels at fast-
ing at all points of the study.
In conclusion, these results suggest that those obese
subjects who regain more weight after a weight-lowering
program appear to present a different central response to
leptin and ghrelin signaling than those that maintain the
body weight loss. Although the mechanisms remain un-
clear, this altered regulation is in the same line as was
found in obesity where leptin levels are higher and ghrelin
levels are lower than in normal-weight subjects. The coun-
terintuitive findings of ghrelin and leptin suggest that
weight regain may be associated with some central or pe-
ripheral resistance to both hormones. On the other hand,
these data concur with a putative proinflammatory state
that could be implicated in the weight rebound.
Acknowledgments
We thank our physician Blanca E. Martínez de Morentin, our
nurse Salome´ Pe´rez, our dietician María Hernandez, and our
technicians Vero´nica Ciaurriz, Ana Lorente, andMaría Amil for
excellent clinical and technical assistance, respectively. Also, we
are grateful to Dr. Paul Miller from the Institute of Modern
Languages of theUniversity ofNavarra for reviewing theEnglish
of the manuscript.
Address all correspondence and requests for reprints to: Dr.
Ana B. Crujeiras, Molecular and Cellular Endocrinology Area
(Lab 2), Instituto de Investigacio´n Sanitaria, Complejo Hospi-
talario de Santiago, C/Choupana, 15706 Santiago de Compos-
tela, Spain. E-mail: anabelencrujeiras@hotmail.com.
This work was supported by Linea Especial about Nutri-
tion, Obesity, and Health (University of Navarra LE/97) and
CIBERobn, an ISCIII initiative. A.B.C. is funded by the Insti-
tuto de Salud Carlos III and the Xunta de Galicia (SERGAS)
through a research-staff contract “Sara Borrell.” M.C.C. is
funded by theXunta deGalicia through a research-staff contract
“Angeles Albarin˜o.”
Disclosure Summary: The authors have nothing to declare.
References
1. Casanueva FF, Moreno B, Rodriguez-Azeredo R, Massien C,
Conthe P, Formiguera X, Barrios V, Balkau B 2009 Relationship of
abdominal obesity with cardiovascular disease, diabetes and hyper-
lipidaemia in Spain. Clin Endocrinol (Oxf) 73:35–40
2. Bray GA, Bellanger T 2006 Epidemiology, trends, and morbidities
of obesity and the metabolic syndrome. Endocrine 29:109–117
3. Abete I, Parra MD, Zulet MA, Martínez JA 2006 Different dietary
strategies forweight loss inobesity: roleof energyandmacronutrient
content. Nutr Res Rev 19:5–17
4. AstrupA,Ro¨ssner S,VanGaalL,RissanenA,NiskanenL,AlHakim
J Clin Endocrinol Metab, November 2010, 95(11):5037–5044 jcem.endojournals.org 5043
M,Madsen J, Rasmussen MF, Lean ME 2009 Effects of liraglutide
in the treatment of obesity: a randomised, double-blind, placebo-
controlled study. Lancet 374:1606–1616
5. Abete I, Parra D, Crujeiras AB, Goyenechea E, Martinez JA 2008
Specific insulin sensitivity and leptin responses to a nutritional treat-
ment of obesity via a combination of energy restriction and fatty fish
intake. J Hum Nutr Diet 21:591–600
6. Abete I, Parra D,Martinez JA 2009 Legume-, fish-, or high-protein-
based hypocaloric diets: effects on weight loss and mitochondrial
oxidation in obese men. J Med Food 12:100–108
7. Aronne LJ, Nelinson DS, Lillo JL 2009 Obesity as a disease state: a
new paradigm for diagnosis and treatment. Clin Cornerstone
9:9–25
8. Schur EA, Cummings DE, Callahan HS, Foster-Schubert KE 2008
Association of cognitive restraint with ghrelin, leptin, and insulin
levels in subjects who are not weight-reduced. Physiol Behav 93:
706–712
9. MacLeanPS,Higgins JA, JackmanMR, JohnsonGC, Fleming-Elder
BK, Wyatt HR, Melanson EL, Hill JO 2006 Peripheral metabolic
responses to prolonged weight reduction that promote rapid, effi-
cient regain in obesity-prone rats. Am J Physiol Regul Integr Comp
Physiol 290:R1577–R1588
10. Levin BE 2004 The drive to regain is mainly in the brain. Am J
Physiol Regul Integr Comp Physiol 287:R1297–R1300
11. Seoane LM, Al-Massadi O, Caminos JE, Tovar SA, Dieguez C,
Casanueva FF 2007 Sensory stimuli directly acting at the central
nervous system regulate gastric ghrelin secretion: an ex vivo organ
culture study. Endocrinology 148:3998–4006
12. Cummings DE 2006 Ghrelin and the short- and long-term regula-
tion of appetite and body weight. Physiol Behav 89:71–84
13. Davis JF, Choi DL, Benoit SC 2010 Insulin, leptin and reward.
Trends Endocrinol Metab 21:68–74
14. Gil-Campos M, Aguilera CM, Can˜ete R, Gil A 2006 Ghrelin: a
hormone regulating food intake and energy homeostasis. Br J Nutr
96:201–226
15. Goyenechea E, Parra D, Crujeiras AB, Abete I, Martínez JA 2009 A
nutrigenomic inflammation-related PBMC-based approach to pre-
dict the weight-loss regain in obese subjects. Ann Nutr Metab 54:
43–51
16. Martínez-Gonza´lez MA, Lo´pez-Fontana C, Varo JJ, Sa´nchez-Villegas
A,Martinez JA 2005 Validation of the Spanish version of the physical
activity questionnaire used in theNurses’ Health Study and theHealth
Profesionals’ Follow-up Study. Public Health Nutr 8:920–927
17. Tremblay A, Coˆte´ J, LeBlanc J 1983 Diminished dietary thermo-
genesis in exercise-trained human subjects. Eur J Appl Physiol Oc-
cup Physiol 52:1–4
18. Crujeiras AB, Parra D, Goyenechea E, Abete I, Martínez JA 2009
Tachyphylaxis effects on postprandial oxidative stress and mito-
chondrial-related gene expression in overweight subjects after a pe-
riod of energy restriction. Eur J Nutr 48:341–347
19. Mera R, ThompsonH, Prasad C 1998How to calculate sample size
for an experiment: a case-based description.NutrNeurosci 1:87–91
20. Osterberg L, Levan K, Partheen K, Delle U, Olsson B, Sundfeldt K,
Horvath G 2009 Potential predictive markers of chemotherapy re-
sistance in stage III ovarian serous carcinomas. BMC Cancer 9:368
21. Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH,
Buchanan TA, Watanabe RM 2005 Sequence variation in PPAR
mayunderlie differential response to troglitazone.Diabetes 54:3319–
3325
22. Campion J, Milagro FI, Goyenechea E, Martinez JA 2009 TNF-
alpha promoter methylation as a predictive biomarker for weight-
loss response. Obesity (Silver Spring) 17:1293–1297
23. de LuisDA, SagradoMG,CondeR,Aller R, IzaolaO 2008Changes
of ghrelinand leptin in response tohypocaloricdiet inobesepatients.
Nutrition 24:162–166
24. Romon M, Gomila S, Hincker P, Soudan B, Dallongeville J 2006
Influence of weight loss on plasma ghrelin responses to high-fat and
high-carbohydrate test meals in obese women. J Clin Endocrinol
Metab 91:1034–1041
25. Abete I, ParraD,DeMorentin BM,AlfredoMartinez J 2009 Effects
of two energy-restricted diets differing in the carbohydrate/protein
ratio on weight loss and oxidative changes of obese men. Int J Food
Sci Nutr 60(Suppl 3):1–13
26. Crujeiras AB, Parra D, Goyenechea E, Martínez JA 2008 Sirtuin
gene expression in humanmononuclear cells ismodulated by caloric
restriction. Eur J Clin Invest 38:672–678
27. MagerU,KolehmainenM,deMelloVD, SchwabU,LaaksonenDE,
Rauramaa R, Gylling H, Atalay M, Pulkkinen L, UusitupaM 2008
Expression of ghrelin gene in peripheral blood mononuclear cells
and plasma ghrelin concentrations in patients with metabolic syn-
drome. Eur J Endocrinol 158:499–510
28. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000
Central nervous system control of food intake. Nature 404:661–
671
29. Ybarra J, Bobbioni-Harsch E, Chassot G, Huber O, Morel P,
Assimacopoulos-Jeannet F, Golay A 2009 Persistent correlation of
ghrelin plasma levels with body mass index both in stable weight
conditions and during gastric-bypass-induced weight loss. Obes
Surg 19:327–331
30. Miljic D, Pekic S, Djurovic M, Doknic M, Milic N, Casanueva FF,
Ghatei M, Popovic V 2006 Ghrelin has partial or no effect on ap-
petite, growth hormone, prolactin, and cortisol release in patients
with anorexia nervosa. J Clin Endocrinol Metab 91:1491–1495
31. Camin˜a JP 2006 Cell biology of the ghrelin receptor. J Neuroendo-
crinol 18:65–76
32. Casanueva FF, Camin˜a JP, CarreiraMC, Pazos Y, Varga JL, Schally
AV 2008 Growth hormone-releasing hormone as an agonist of the
ghrelin receptor GHS-R1a. Proc Natl Acad Sci USA 105:20452–
20457
33. Tups A 2009 Physiological models of leptin resistance. J Neuroen-
docrinol 21:961–971
34. Nogueiras R, Tscho¨p MH, Zigman JM 2008 Central nervous sys-
tem regulation of energymetabolism: ghrelin versus leptin. AnnNY
Acad Sci 1126:14–19
35. Parra D, Ramel A, Bandarra N, Kiely M, Martínez JA, Thorsdottir
I2008Adiet rich in long chainomega-3 fatty acidsmodulates satiety
in overweight and obese volunteers during weight loss. Appetite
51:676–680
36. RamelA,Martínez JA,KielyM,MoraisG,BandarraNM,Thorsdottir
I 2008 Beneficial effects of long-chain n-3 fatty acids included in an
energy-restricted diet on insulin resistance in overweight and obese
European young adults. Diabetologia 51:1261–1268
37. Procaccini C, Lourenco EV, Matarese G, La Cava A 2009 Leptin
signaling: a key pathway in immune responses. Curr Signal Trans-
duct Ther 4:22–30
38. De Vriese C, Delporte C 2008 Ghrelin: a new peptide regulating
growth hormone release and food intake. Int J Biochem Cell Biol
40:1420–1424
39. Considine RV, Premkumar A, Reynolds JC, Sebring NG, Ricks M,
SumnerAE2008Adiponectinand leptin inAfricanAmericans.Obe-
sity (Silver Spring) 16:428–434
40. Makovey J, Naganathan V, Seibel M, Sambrook P 2007 Gender
differences in plasma ghrelin and its relations to body composition
and bone: an opposite-sex twin study. Clin Endocrinol (Oxf) 66:
530–537
5044 Crujeiras et al. Appetite Hormones and Regain of Weight J Clin Endocrinol Metab, November 2010, 95(11):5037–5044
